Navigation Links
Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
Date:5/31/2011

CRANBURY, N.J., May 31, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Matthew R. Patterson, President and Acting Chief Executive Officer, will present a corporate overview at the Jefferies 2011 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 12:15 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(tm) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
2. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
3. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
4. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
5. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
6. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
7. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
8. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
9. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
10. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
11. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/21/2013)... According to a May 13, 2013 New Zealand Herald ... Botox injections have become the most popular cosmetic procedure ... goo.gl/8iYbD). Although it is mostly associated with women, Botox ... facial wrinkles less visible by paralyzing facial muscles. The effects ... This means that people who are conscious about their looks ...
(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 ... sports organization, and Bodybuilding.com, the largest online retailer of ... you a new reality-based sports show, Warrior Island. ... vote on; YouTube, Facebook & Twitter, with our unique ... Warrior Island maroons these elite fighters on an island ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
(Date:5/21/2013)... The Las Vegas personal injury law firm Benson, Bertoldo, ... a senior at Coronado High School, is the winner of ... As the winner of the essay contest, Crawford received a ... 1, 2012 and ran through April 30th, 2013. Participating senior ... essay on “The Role of the civil tort system.” The ...
(Date:5/21/2013)... May 21, 2013 While North Carolina ... with comprehensive travel guides. Brunswick Plantation & Golf Resort ... that include access to 27 holes of "Top10" championship ... in North Carolina, knowing the Top 10 ... takes away the overwhelming task of selecting the course ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... Recognize Efforts to Safeguard Sight, Promote Healthy Vision ... for Children and Expand Access to ... was recognized for providing important leadership on health care,policy issues ... the 34,000 member American Optometric Association (AOA).,Optometrists in West Virginia ...
... Will Follow 60,000 Women for 5 Years, ... aged 55,years and older have enrolled in a ... of osteoporosis across the globe. Launch of the,Global ... announced,today at ECCEO 8 (Eighth European Congress on ...
... at Tri-City Medical Center (TCMC) achieved union recognition,Wednesday ... Service,confirmed that caregivers strongly supported unionization and had ... TCMC caregivers become members of SEIU United Healthcare ... workers who have achieved industry a,voice on the ...
... month of tough breathing may help asthma sufferers breathe easier ... of Houston professor. , In a move that ... Oath first do no harm Richard Bond, associate ... medical taboo to treat asthma. Although counterintuitive, Bonds studies ...
... under control , , WEDNESDAY, April 9 (HealthDay News) -- In ... swept across eight Midwestern states, but a new study claims ... outbreak was limited, because the number of people in the ... high, explained study co-author Amy A. Parker, from the ...
... Mr. Muneo Takashi has been,named to head ... Organization,(JETRO Chicago). As the new Chief Executive Director, ... completing his assignment in Chicago., As Chief ... in its activities designed to facilitate business development,between ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 3Health News:North County Caregivers Join United Healthcare Workers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Mumps Outbreak in Midwest Could Have Been Worse 2Health News:Mumps Outbreak in Midwest Could Have Been Worse 3Health News:Muneo Takashi Named Chief Executive Director of Japan's Midwest Trade Office 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: